Home > Boards > US Listed > Medical - Drugs > Cerus Corporation (CERS)

I ran a 10-year chart on $CERS to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mdimport Member Profile
 
Followed By 169
Posts 17,463
Boards Moderated 1
Alias Born 03/21/10
160x600 placeholder
Cerus Corporation Announces New Five-Year INTERCEPT Blood System Agreement With Swiss Transfusion SRC Business Wire - 12/12/2019 8:30:00 AM
Cerus Corporation to Present at the Stifel 2019 Healthcare Conference Business Wire - 11/13/2019 8:30:00 AM
Cerus Corporation to Present at the Stephens Nashville Investment Conference Business Wire - 11/8/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 5:57:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/30/2019 4:05:31 PM
Cerus Corporation Announces Third Quarter 2019 Results Business Wire - 10/30/2019 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/28/2019 7:56:43 PM
Cerus Corp. to Release Third Quarter 2019 Results & to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on Octob... Business Wire - 10/21/2019 8:30:00 AM
Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting Business Wire - 10/18/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/15/2019 4:48:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/4/2019 7:19:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/4/2019 7:11:05 PM
Cerus Corp. Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection & T... Business Wire - 9/30/2019 12:00:00 PM
Cerus Corporation to Present at the 2019 Cantor Global Healthcare Conference Business Wire - 9/27/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/18/2019 6:47:42 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 9/17/2019 12:49:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2019 3:02:31 PM
Cerus Corporation to Participate in Upcoming Investor Conferences Business Wire - 8/28/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/20/2019 7:01:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/9/2019 5:13:25 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/9/2019 1:12:02 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/1/2019 5:28:31 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 5:13:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:06:59 PM
Cerus Corporation Announces Record Second Quarter 2019 Results Business Wire - 8/1/2019 4:01:00 PM
mdimport   Friday, 05/26/17 10:07:32 AM
Re: kevinraugust25 post# 298
Post # of 320 
I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.



Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."

The paradox of iHub: buy high, sell low
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist